Melanoma vaccine: what the 42 percent risk reduction means
Merck and Moderna publish phase III results for the personalised therapy. The benefit combines relapses and deaths – a longer overall survival has not yet been demonstrated.
Merck and Moderna published detailed results of their phase III trial INTerpath-001 on 22 October 2026. According to the companies, the combination of the personalised mRNA therapy intismeran autogene and pembrolizumab reduced the event rate for relapse or death by 42 percent relative to the comparator treatment. That is more than the earlier statement that the trial had met its goals. The figure is not a cure rate.
The trial studied people whose melanoma had been fully surgically removed and who had a high risk of relapse. The comparison was against pembrolizumab plus placebo. The new therapy therefore replaces neither surgery nor the existing treatment. It is given on top. The publicly accessible trial registry describes a randomised, blinded design.
Random allocation is meant to make the groups as comparable as possible. Blinding reduces the influence of expectations on the assessment. Even so, it still matters who funds and reports the study: the current results announcement comes from the manufacturers. Assessment by the specialist community and by regulators must be kept separate from that.
A figure about events over time
The 42 percent rests on a hazard ratio of 0.58. Such a measure compares event rates between two groups over the observation period. It does not say that a relapse was prevented in 42 of 100 treated people. Nor does it mean that any single person now has a particular probability of being cured.
This distinction is more than statistical pedantry. To make a treatment decision, it must be clear how often an event occurs without the additional therapy and what difference the treatment makes at a given point in time. A relative change can sound impressive without stating the baseline. Without a reference point, its practical benefit therefore remains incompletely described.
After two years, the companies report 82.2 percent free of relapse or death in the combination group and 70.0 percent in the comparator group. The difference comes to 12.2 percentage points. This time-bound comparison is not the same as the hazard ratio: it describes the estimated state after two years, while the hazard ratio describes the course over time.
Relapse-free survival is not overall survival
The primary endpoint bundles two different events: the return of the disease and death. Anyone who lives longer without a relapse has a relevant advantage. But that does not automatically mean that total lifespan is demonstrably extended. This question must be examined separately.
According to the manufacturers, the overall survival data are not yet mature. This limitation belongs next to the positive news, not in a footnote. Even a favourable trend is not yet confirmed proof. For the longer-term assessment it therefore remains important how both groups develop with further follow-up.
Why it is not an ordinary preventive vaccine
The term cancer vaccine can raise false expectations. The US National Cancer Institute explicitly distinguishes between preventive vaccines and therapeutic vaccines. The latter are aimed at people who have cancer. They are intended to help the body's own immune defences recognise features of cancer cells more effectively.
In personalised approaches, the treatment is adapted to the characteristics of the individual tumour. The mRNA supplies a blueprint for target structures that the immune system is meant to respond to. It is not a general protection against all types of cancer. Whether a result can be transferred to other diseases must also be examined anew in each case.
The manufacturers also report on safety: treatment-related adverse events of severity grades 3 to 5 occurred in 14.2 percent of the combination group and 13.4 percent of the comparator arm. These figures must be distinguished from the frequency of all adverse events, including milder ones.
An additional immunotherapy should also not be judged by its efficacy figure alone. For those affected, what counts are possible side effects, the burden of treatment and check-ups, and their own disease situation. General information about cancer vaccines therefore does not replace advice from the treating oncology team.
What matters for patients in Switzerland
A company announcement is not a Swiss approval decision. Swissmedic assesses quality, safety and efficacy on the basis of the submitted scientific documentation. What counts is a positive benefit-risk assessment. When granting approval, the authority also sets the authorised product information.
Until these questions are clarified, patients should not change their ongoing therapy because of a headline. The new finding is a well-founded reason for hope and further scrutiny. Its concrete value lies in additional protection against certain events after surgery – not in the promise that cancer has been defeated in general.
Sources
- Merck and Moderna: original announcement of 22 October 2026, at MarketScreener
- ClinicalTrials.gov: trial registry INTerpath-001
- National Cancer Institute: definition of the hazard ratio
- National Cancer Institute: therapeutic cancer vaccines
- National Cancer Institute: mRNA vaccines in cancer therapy
- Swissmedic: tasks and approval review
